Effects of Fesoterodine, a Novel Antimuscarinic, Alone and in Combination with an α-Receptor Blocker, Doxazosin, on Bladder Function in Obstructed Rats

This document reviewed the effects of fesoterodine, an antimuscarinic, and doxazosin, an α-receptor blocker, on bladder function in obstructed rats, within the context of treating benign prostatic hyperplasia (BPH) in older men. It highlighted that while α-blockers and 5α-reductase inhibitors are commonly used for BPH, evidence for their combination was not always supportive. The MTOPS trial, a significant study, showed that combination therapy reduced clinical progression rates more effectively than monotherapy with doxazosin or finasteride alone. Finasteride was found to reduce the risk of acute urinary retention and surgery, particularly in men with larger prostates. Overall, combination therapy was shown to relieve symptoms and delay BPH progression in men with moderate to severe symptoms and moderately enlarged prostates.